This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or registerLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcasts3D Body AtlasLet’s connectLet's connectContact usSign up

Adverse event reporting can be found at the bottom of the page

Home

Menu

Close

EfficacyEfficacy Home PageTrial DesignClinical RemissionEarly Symptomatic ResponseEndoscopic ImprovementBio/JAKi Subgroups DataIsolated ProctitisSafetyAdverse eventsCardiac and ocular adverse eventsGetting StartedResourcesMaterialsVideosPrescribing InformationPrescribing Information 
The convenience of one pill, once a day1

With VELSIPITY®, you can offer patients 16 years of age and older1:

 One pill, once a day

2 mg orally once daily, taken with food for the first 3 days, then with or without food thereafter*

 The same dose right from the start—no titration required

The initiation dose is the maintenance dose

 Recommended monitoring for certain safety signals, but no unique required scheduled monitoring† No known interactions with monoamine oxidase (MAO) inhibitors or tyramine.1No required scheduled monitoring outside of standard clinical assessments. Safety signals should be monitored during treatment and managed appropriately, as recommended in the Summary of Product Characteristics for VELSIPITY® (etrasimod).Getting started with VELSIPITY®

Test to determine if VELSIPITY® is appropriate for patients before starting treatment1
  • Exclude patients who1:
    • Had certain cardiovascular conditions,* including stroke, in the last 6 months
    • Are or who plan to become pregnant
  • Please see Summary of Product Characteristics1 for all contraindications and special warnings and precautions for use
  • Obtain a recent (ie, within the last 6 months or after discontinuation of prior UC therapy) complete blood count with differential and liver function tests—including lymphocyte count, transaminase levels, and bilirubin levels
  • Electrocardiogram (ECG or EKG)
  • Pregnancy test
A reminder of other standard assessments
  • Vaccinations (recommended to update immunisations in agreement with current guidelines—no herpes zoster vaccine is required)
  • Obtain an eye exam of the fundus, including the macula, near or following the start of treatment to screen for any preexisting eye conditions. Patients with a history of diabetes mellitus, uveitis, or an underlying/coexisting retinal disease are recommended to undergo an eye exam regularly during treatment1

AFTER THE LAST DOSE1:

  • Women of childbearing potential should use effective contraception for at least 14 days
  • Vigilance for infection should be continued for up to 2 weeks
  • Use of live attenuated vaccine should be avoided for up to 2 weeks due to risk of infection
 Patients in the last 6 months who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischaemic attack (TIA), decompensated heart failure requiring hospitalization, or New York Heart Association (NYHA) class III or class IV heart failure. Patients with history or presence of Mobitz type II second-degree or third-degree atrioventricular (AV) block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker.1Due to the risk of transient decreases in heart rate with the initiation of VELSIPITY®, a 4-hour monitoring for signs and symptoms of symptomatic bradycardia after the first dose is recommended in patients with resting heart rate <50 bpm, second-degree AV block (Mobitz type I), or a history of myocardial infarction or heart failure.1 Resources for your patients

See the different resources available to help your patients start and stay on VELSIPITY®.

 See Resources Loading▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.References:
1.VELSIPITY® Summary of Product Characteristics available on medicines.ie.
2. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies [published correction appears in Lancet. 2023;401(10381):1000]. Lancet. 2023;401(10383):1159-1171

Further Information is available on request.
Legal Category S1A

PP-V1A-IRL-0037 Date of preparation June 2025

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.Registered in the Republic of Ireland No. 127002. Directors: M. Adamson (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

 

Copyright © 2025 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0937. July 2025
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0901. July 2025
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0901. July 2025

Yes No